Exigyn’s Post

Every year, the Novo Nordisk Foundation reports on progress in research advancements, inventions, and patient treatment. The impact report serves as a testament to the Foundation's commitment to making a significant scienfic and broader societal impact on public health, sustainable development and the condition of the planet. One of the analyses in the report investigates the research the funded and how it underpins development of technology. For the first time, we see Industrial Biotechnology as one of the most common areas of research and Climate Change Mitigation Technology as one of the most common patent technology classifications highlighting - an early indication of the Foundation's shift in strategy to also focus on the sustainability of the planet. Read the report here: https://lnkd.in/dbRdkU5K The team behind the report is the Impact Area: Thomas Alslev Christensen, Henrik Barslund Fosse, Gert V. Balling, Rikke Christensen, Joan Bentzen, Rasmus Lund Jensen, Daryl Paul, Sandra Schluttenhofer, Emil Søndergaard Hansen, Anders Agerbæk Kjøller Nielsen, Kristian Raudal, Jens Christian Petersen.

What does the birth of Scion Life Sciences mean for the world of Biotech?🔬 Leading on from my post yesterday, I thought it would be interesting to delve deeper into some insights around the VC launch. Approach: The firm aims to catalyze the development of smaller but more 'durable' start-ups with the means to access necessary funding & resources to make an impact in their field. The curation of their portfolio will very much be based on QUALITY and not quantity in order to accelerate areas with less competition. Investment Strategy: 3 investment pillars that have been presented demonstrate their strategic & pragmatic principals. 1. Mature Modalities 2. Well-Understood Biology & Pathophysiology 3. Standalone Viability 👀 The 'standalone viability' particularly caught my eye as I like the fact they are focusing on companies that don't rely on large-scale commercial/pharma resources to make an impact. #biotech #vcfunding #scionlifesciences #biotechfunding

April 10 at 6pm PT. We have another incredible Innovator’s Workbench event planned, featuring Ted W. Love, MD, chair of the board of the Biotechnology Innovation Organization. Innovation Fellowship alum Uday Kumar, a senior advisor at Stanford Biodesign, will chat with Dr. Love about his journey into biotechnology innovation and the need to take on large, complex challenges to drive greater health equity for all populations. Don’t miss it!  Registration link in the comments. #innovationeducation #biotech #healthtech #healthequity

How to fund your life sciences innovation? If you are a researcher or a startup, this workshop will showcase the optimal financing strategy and timeline

Follow Amix Tech to read interesting news around the world Sigan Amix Tech para leer interesantes noticias de alrededor del mundo

#BioTechNews #TechNews by Max Morales Why Is The FBI Sourcing Enzymes From #Patagonia For Drug Detection? Kura Biotech is the biggest enzyme-producer you've never heard of. They’ve bootstrapped their way to protein engineering prowess all from deep in the heart of South America. Their story shows what’s possible if we break convention and build mission-driven science companies outside of the traditional epicenters of innovation. In the wake of the pandemic, remote work is in vogue. That was not the case ten years ago. And even today, with more and more companies shirking brick and mortar, biologists are slow to adapt. Admittedly, lab work cannot occur in a living room. Scientists need physical spaces to work. But they don’t need to be shoulder to shoulder with everyone they work with. Kura Biotech realized this early. “Even before the pandemic, we were convinced that you could be connected to the world without being right in the middle of things,” said Manuel Rozas Chief Scientific Officer and Founder of Kura Biotech when I spoke with him ahead of the SynBioBeta conference. While most would have advised him to go court venture capitalists in The Bay Area and Boston, Rozas turned to a town of 40,000 people in South Chile. Read more: https://lnkd.in/e_upGXRR By John Cumbers via Forbes

On this International Women’s Day, let’s recognize and honor the remarkable contributions of women in science. 🚀🔬 🌱 Camila Jiménez-Gonzalez, a dedicated researcher from our ALEHOOP project, eloquently captures the essence of science: “Science embodies curiosity, tirelessly seeking answers to questions yet unexplored and consistently achieving remarkable breakthroughs. It contributes immensely across various domains, enriching our understanding and shaping our reality. Science is knowledge.” 🔍 In their Biochemistry Lab, they play a pivotal role in shaping projects, with a special focus on plant-based molecules. Within ALEHOOP, we delve into the fascinating world of plant-based proteins, unraveling their secrets and potential applications. 🌿 Let’s celebrate the brilliance of women like Camila, who drive innovation, ignite curiosity, and inspire generations to come. 🌟 #WomenInScience #GirlsInSTEM

Thank you, James Zanewicz, JD, LLM, RTTP, for the generous T2B shoutout in your latest BIO from the BAYOU episode! Commenting on T2Bmeet @ BIO: "It was really fascinating to have the communicators who were out there [at #BIO2024] trying to explain what companies are doing -- both to potential customers, to investors. The comms and brand is so present in everything." Definitely add this one to your weekend podcast list, and hear what else James had to say about T2B starting at the 13:07 mark!

🌱🔬 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐲 𝐀𝐥𝐞𝐫𝐭: 𝐋𝐨𝐰-𝐂𝐨𝐬𝐭 𝐂𝐮𝐬𝐭𝐨𝐦 𝐏𝐡𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐀𝐜𝐜𝐞𝐬𝐬 𝐓𝐫𝐢𝐚𝐥𝐬! 🔬🌱 PhenomUK is thrilled to announce a groundbreaking funding opportunity aimed at tackling the challenges of low-cost custom phenomics. 🚀 We're calling upon researchers and innovators across the UK to submit their proposals for projects focusing on the development, application, and replicability of affordable, tailored phenomics equipment. 🎯 Our Goal:  Our aim with this initiative is clear: to empower researchers by providing the tools they need to conduct phenomics experiments without breaking the bank. We're seeking projects that refine existing equipment for replication or implement designs from elsewhere, fostering collaboration and resource-sharing within the plant phenomics community. 🛠 What We're Looking For:  Applications may involve the development of custom sensors, imaging devices, or other phenomics tools. Whether it's standardizing a proprietary kit for wider use or overcoming technical barriers, we're eager to support projects that push the boundaries of innovation in phenomics research. 🌟 Why You Should Apply:  Gain funding to advance your phenomics solutions.  Contribute to the growth of the UK research community.  Address technical challenges and foster collaboration.  Make a meaningful impact on plant phenomics research. ⏰ Apply Now:  Applications will be reviewed on a rolling basis, so don't delay! Head over to the PhenomUK website for more details and to submit your proposals. With limited funding available, seize this opportunity to drive change and make your mark in the world of phenomics. 🌿 Together, Let's Grow:  We're excited to see the innovative proposals that emerge from this call and to work together in advancing low-cost custom phenomics solutions. Join us on this journey as we pave the way for a brighter future in plant research! #PhenomicsResearch #Innovation #FundingOpportunity #PhenomUK #ResearchCommunity International Plant Phenotyping Network - IPPN PhenomUK Research Infrastructure Tracy Lawson Claire Hayes

#SpainIsBiotech🧬 | #Biotech companies have the most researchers and 60% of all employees are women. #Talent: The sector continues to interest young students, with more than 8,900 students enrolled in university studies in biotechnology last year, 62% of which were women. #Diversity: On the ranking of women working in R&D as a percentage of total R&D staff, biotech companies remained third, with 58%, and on the ranking of female R&D workers as a percentage of all employees they remained second with 7.52%. Women still only make up 28.4% of executive teams at biotech firms. #AseBioReport2022 ➡ https://lnkd.in/e5u3DrmR #WeAreBiotech